Bli medlem
Bli medlem

Du är här


Alzinova: Alzinova publishes the Annual Report for 2019

The Board of Directors and the Chief Executive Officer of Alzinova AB
hereby present the Annual Report of the financial year 2019.

The Annual Report, which is attached in the press release, can also be
downloaded from the company's Swedish website,

For more information, please contact:

Kristina Torfgård, CEO

Telephone: +46 70 846 79 75


Certified Adviser:

Corpura Fondkommission AB


Telephone: 0768-532822


About Alzinova AB

Alzinova AB is engaged in pharmaceutical research and development for
treatment of Alzheimer's disease - one of our major health scourges,
without efficient treatment options. The Company's patented
technology enables the development of novel therapies, that with high
precision could target the substances involved in the formation of
the disease and render them harmless. Alzinova's focus is to develop
a vaccine as a long-acting therapy for treatment and prevention of
Alzheimer's disease. The vaccine is currently under preclinical
development, in preparation for human clinical trials. The Company
further conducts development within diagnostics for the disease.
Alzinova was founded by researchers from the MIVAC research center at
the University of Gothenburg, and by GU Ventures AB.


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.